Malaysian Genomics Resource (0155) - Total Assets
Based on the latest financial reports, Malaysian Genomics Resource (0155) holds total assets worth RM21.40 Million MYR (≈ $5.37 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Malaysian Genomics Resource to assess how comfortably operating cash covers total debt obligations.
Malaysian Genomics Resource - Total Assets Trend (2015–2026)
This chart illustrates how Malaysian Genomics Resource's total assets have evolved over time, based on quarterly financial data. See Malaysian Genomics Resource (0155) shareholders funds for net asset value and shareholders' equity analysis.
Malaysian Genomics Resource - Asset Composition Analysis
Current Asset Composition (June 2026)
Malaysian Genomics Resource's total assets of RM21.40 Million consist of 51.0% current assets and 49.0% non-current assets.
| Asset Category | Amount (MYR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | RM0.00 | 5.5% |
| Accounts Receivable | RM2.60 Million | 13.9% |
| Inventory | RM390.50K | 2.1% |
| Property, Plant & Equipment | RM0.00 | 0.0% |
| Intangible Assets | RM3.46 Million | 18.5% |
| Goodwill | RM0.00 | 0.0% |
Asset Composition Trend (2015–2026)
This chart illustrates how Malaysian Genomics Resource's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 0155 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Malaysian Genomics Resource's current assets represent 51.0% of total assets in 2026, an increase from 39.7% in 2015.
- Cash Position: Cash and equivalents constituted 5.5% of total assets in 2026, up from 0.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 11.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 18.5% of total assets.
Malaysian Genomics Resource Competitors by Total Assets
Key competitors of Malaysian Genomics Resource based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
INIFY LABORATORIES AB
F:WY60
|
Germany | €204.64 Million |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩131.23 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA
|
India | Rs15.07 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
Malaysian Genomics Resource - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.53 | 3.08 | 30.10 |
| Quick Ratio | 5.26 | 2.85 | 30.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | RM10.30 Million | RM7.50 Million | RM17.81 Million |
Malaysian Genomics Resource - Advanced Valuation Insights
This section examines the relationship between Malaysian Genomics Resource's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.26 |
| Latest Market Cap to Assets Ratio | 0.60 |
| Asset Growth Rate (YoY) | -16.3% |
| Total Assets | RM18.71 Million |
| Market Capitalization | $11.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values Malaysian Genomics Resource's assets below their book value (0.60x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Malaysian Genomics Resource's assets decreased by 16.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Malaysian Genomics Resource (2015–2026)
The table below shows the annual total assets of Malaysian Genomics Resource from 2015 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | RM18.71 Million ≈ $4.70 Million |
-16.31% |
| 2025-06-30 | RM22.36 Million ≈ $5.61 Million |
-13.03% |
| 2024-06-30 | RM25.70 Million ≈ $6.45 Million |
-16.74% |
| 2023-06-30 | RM30.87 Million ≈ $7.75 Million |
-26.30% |
| 2022-06-30 | RM41.89 Million ≈ $10.52 Million |
+83.86% |
| 2021-06-30 | RM22.78 Million ≈ $5.72 Million |
+105.51% |
| 2020-06-30 | RM11.09 Million ≈ $2.78 Million |
-70.04% |
| 2019-06-30 | RM37.00 Million ≈ $9.29 Million |
-9.39% |
| 2018-06-30 | RM40.84 Million ≈ $10.25 Million |
+8.05% |
| 2017-06-30 | RM37.80 Million ≈ $9.49 Million |
+76.08% |
| 2016-06-30 | RM21.47 Million ≈ $5.39 Million |
-1.16% |
| 2015-06-30 | RM21.72 Million ≈ $5.45 Million |
-- |
About Malaysian Genomics Resource
Malaysian Genomics Resource Centre Berhad, together with its subsidiaries, provides genetics, genomics, immunotherapy, and biopharmaceutical services in Malaysia. The company offers genetic screening services that includes Dtect and Origene genetic testing solutions which provides individuals with insights into genetic predispositions related to health risks, wellness, and lifestyle traits. It al… Read more